Today: 30 April 2026
Oracle stock jumps after Goldman’s Buy call as AI buildout costs stay in focus
12 January 2026
2 mins read

Oracle stock jumps after Goldman’s Buy call as AI buildout costs stay in focus

New York, January 12, 2026, 17:11 EST — after-hours trading

  • Oracle shares climbed roughly 3% in late trading following Goldman Sachs’ debut coverage, which included a Buy rating and a $240 price target.
  • Goldman noted that AI is broadening the software market, though investors remain focused on which companies can convert that demand into lasting profits.
  • At NRF in New York, Oracle unveiled a new retail supply-chain cloud tool and secured a new hospital client for Oracle Health.

Oracle Corp shares climbed 3.1% to $204.68 in after-hours trade Monday, bouncing between $194.91 and $206.58 during the session. The jump followed Goldman Sachs initiating coverage with a Buy rating and setting a $240 price target.

The call comes at a tricky time for big-cap software. Investors crave AI-driven cloud growth but are quick to punish spending that clouds the outlook for cash flow and margins.

Oracle occupies a middle ground in this balancing act. The company provides the essential infrastructure — databases, business software, and cloud services — and has increasingly linked its offering to AI workloads, where data centers and energy costs often outpace revenue growth.

Goldman Sachs analyst Gabriela Borges expressed a “constructive” view on AI adoption, seeing it as a boost to the software total addressable market (TAM). However, she cautioned that annual “datapoints may be uneven as the ecosystem matures.” Borges highlighted the main question: which companies can turn AI infrastructure demand into “a sustainable, profitable business.” Goldman projects infrastructure software providers will push gross margins — a key profitability metric — from “<40% to 60%+.” Investing.com

Oracle rolled out new product updates on Sunday, launching Oracle Retail Supply Chain Collaboration. This cloud-based tool aims to help retailers share data with suppliers and keep compliance in check amid rising disruption risks. “Retailers are in a constant battle to better balance their supply chains,” said Paul Woodward from Oracle Retail. Oracle

On Monday, Oracle announced that Community Memorial Hospital in Central New York will replace its outdated health record systems with Oracle Health Foundation EHR — electronic health records. The hospital will also deploy Oracle Health Clinical AI Agent to automate clinical documentation. “Choosing Oracle Health is a pivotal step in our journey to modernize and unify our clinical systems,” said CMH President and CEO Jeffery Coakley. Oracle Health chief Seema Verma added that the aim is to deliver “integrated, AI-powered solutions” tailored for smaller hospitals. Oracle

AI infrastructure news is also shaping Oracle’s cloud narrative. OpenAI and SoftBank plan to pour $1 billion into SB Energy for a 1.2-gigawatt Stargate data center in Texas. Stargate, a venture launched alongside OpenAI, SoftBank, Oracle, and MGX, targets $500 billion in infrastructure spending over four years. Greg Brockman, OpenAI’s co-founder and president, called the partnership “a fast, reliable way to scale compute.” DataCenterDynamics

Oracle’s bet depends on turning those hefty AI workloads into steady, higher-margin cloud revenue—not merely expanding capacity. The company is also pushing to grab market share from bigger cloud rivals, with pricing and power limits playing a key role in the investment story.

The risk is clear: costs could outpace demand, or demand might arrive in fits and starts, causing uneven utilization. That scenario would squeeze margins and push the market to revisit a familiar dilemma — just how much spending crosses the line.

Investors are now looking for follow-up from other broker reports after Goldman’s call, along with any new customer wins linking Oracle’s retail and healthcare efforts to actual bookings. Oracle remains in the thick of NRF 2026 in New York through Jan. 13, showcasing its retail supply-chain solution.

Stock Market Today

  • KONE Oyj Shares Show Weakness, Valuation Analysis Signals Overvaluation
    April 30, 2026, 8:50 AM EDT. KONE Oyj's share price dropped 4.6% last week and 1.7% last month, despite a 3% gain over the past year. The company, a key player in global elevators and escalators, faces scrutiny as infrastructure demand impacts investor sentiment. Our Discounted Cash Flow (DCF) model projects an intrinsic value of €47.26 per share, indicating the current price of €54.46 is roughly 15.2% overvalued. The firm scores 0/6 on valuation checks, raising red flags for potential investors. The Price-to-Earnings (P/E) ratio, another metric for assessing stock value tied to earnings, also factors into ongoing valuation debates. The mixed returns across 1, 3, and 5 years heighten questions about KONE's long-term investment appeal amid market uncertainty.

Latest article

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM
Previous Story

Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up
Next Story

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Go toTop